Charles Schwab Investment Management Inc. Cuts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Charles Schwab Investment Management Inc. reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,586,803 shares of the biopharmaceutical company’s stock after selling 80,468 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Amicus Therapeutics were worth $24,368,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $55,000. R Squared Ltd acquired a new stake in Amicus Therapeutics during the 4th quarter worth approximately $79,000. KBC Group NV increased its position in Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 3,120 shares in the last quarter. Stephens Inc. AR acquired a new stake in Amicus Therapeutics during the 4th quarter worth approximately $101,000. Finally, Choreo LLC acquired a new stake in Amicus Therapeutics during the 4th quarter worth approximately $103,000.

Amicus Therapeutics Stock Down 1.5 %

Shares of NASDAQ:FOLD opened at $8.98 on Wednesday. Amicus Therapeutics, Inc. has a 52-week low of $8.55 and a 52-week high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -49.89, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a 50 day moving average of $9.36 and a two-hundred day moving average of $10.11.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Amicus Therapeutics has an average rating of “Moderate Buy” and an average price target of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.